The MARBLE Study Protocol: Modulating ApoE signaling to Reduce Brain inflammation, deLirium, and postopErative Cognitive Dysfunction

Manuscript Number: 

19-1185R2

Author(s): 
Oke Anakwenze, Miles Berger, Michael P. Bolognesi, Jeffrey N. Browndyke, Mary Cooter, Donna M. Crabtree, Michael J. Devinney, Mark E. Easley, Sarada Eleswarpu, Michael N. Ferrandino, William A. Jiranek, Daniel T. Laskowitz, Eugene W. Moretti, Kenneth C. Roberts, Frank W. Rockhold, Keith W. VanDusen, John Whittle, Marty G. Woldorff

Disclosures

Oke Anakwenze

  • Nothing to Disclose

Miles Berger

  • Consulting Fees:
    Private consulting for 2 legal cases related to postoperative cognition in older adults. MB has also participated in a peer to peer educational session for Massimo Inc in 2019, for which his $1000 honorarium was donated directly at his request to the Foundation for Anesthesia Education & Research.

Michael P. Bolognesi

  • Equity:
    TJO- stock ownership
    Patents/Royalties
    Zimmer Biomet- Royalties, Design Surgeon TJO- Royalties, Design Surgeon
    Grants
    • Agency: 
      Depuy Synthes, Zimmer Biomet, Stryker, Exactech,
      Dates: 
      2005 to present

Jeffrey N. Browndyke

  • Nothing to Disclose

Mary Cooter

  • Nothing to Disclose

Donna M. Crabtree

  • Nothing to Disclose

Michael J. Devinney

  • Nothing to Disclose

Mark E. Easley

  • Nothing to Disclose

Sarada Eleswarpu

  • Nothing to Disclose

Michael N. Ferrandino

  • Nothing to Disclose

William A. Jiranek

  • Consulting Fees:
    Depuy Synthes - Consult on Hip and Knee prosthesis design and function
    Patents/Royalties
    Royalties for IP from certain hip and knee prostheses - Depuy Synthes Orthopaedics

Daniel T. Laskowitz

  • Equity:
    DTL serves as a principle and has equity in in Aegis-CN, which is supplying drug and has out-licensed CN-105 from Duke University. Aegis had no role in study design or content of this manuscript.
    Patents/Royalties
    DTL is a full time employee of Duke University, which owns intellectual property associated with CN-105

Eugene W. Moretti

  • Nothing to Disclose

Kenneth C. Roberts

  • Nothing to Disclose

Frank W. Rockhold

  • Consulting Fees:
    Dr. Rockhold reports grants consulting fees from Janssen, Merck HeathCare KGaA, Eidos, Amgen, Phathom and Sarepta. DSMB reimbusement from Merck Research Labs, NovoNordisk, KLSMC Stem Cells, Aldeyra, Rhythm, AstraZeneca, Complexa, Lilly, and Novartis. Advisory Boards for Athira, DataVant and Spencer Health Solutions
    Equity:
    GlaxosmithKline Share Ownership and equity options in Athira, Spencer and DataVant
    Grants
    • Agency: 
      AstraZeneca
      Dates: 
      2016-
    • Agency: 
      Eidos
      Dates: 
      2019-
    • Agency: 
      Reneuron
      Dates: 
      2016-
    • Agency: 
      American Regent
      Dates: 
      2017-
    • Agency: 
      BMS
      Dates: 
      2018-

Keith W. VanDusen

  • Nothing to Disclose

John Whittle

  • Nothing to Disclose

Marty G. Woldorff

  • Nothing to Disclose